- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT00998296
Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.
A tanulmány áttekintése
Tanulmány típusa
Beiratkozás (Tényleges)
Fázis
- 1. fázis
Kapcsolatok és helyek
Tanulmányi helyek
-
-
-
Villejuif Cedex, Franciaország
- 1239.14.3301A Boehringer Ingelheim Investigational Site
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion criteria:
- Patients with confirmed histological or cytological diagnosis of advanced solid tumours and for whom no proven therapy exists or who are not amenable to established treatments.
- Age 18 years or older.
- Life expectancy of at least three months.
- Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.
- Patients previously treated and with asymptomatic brain metastases are eligible
- Patients must have recovered from recent surgery.
Exclusion criteria:
- Active infectious disease
- Recent surgery within the last 4 weeks prior visit 1.
- Chronic diarrhoea or gastrointestinal tract disease resulting in an inability to take oral medication
- History of haemorrhagic or thrombotic events
- Significant cardiovascular diseases within
- Current peripheral neuropathy > Common Terminology Criteria for Adverse Events (CTCAE) grade 1 except due to trauma
- Untreated or symptomatic brain metastases or leptomeningeal disease.
- Treatment with an Epidermal growth Factor-receptor (EGFR)- or Heregulin Receptor 2 (HER2) inhibiting drug or antiangiogenic drug.
- Therapeutic anticoagulation.
- Female patients of childbearing potential.
- Known pre-existing interstitial lung disease
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: N/A
- Beavatkozó modell: Egyetlen csoportos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
---|---|
Kísérleti: BIBW 2992 + BIBF 1120
This is a phase I dose escalation clinical trial and the data obtained shall determine the MTD for the combination of BIBW 2992/BIBF 1120 in 28-day of treatment.
|
VEGF inhibitor
EGFR inhibitor
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Maximum Tolerated Dose (MTD) of Nintedanib and Afatinib Based on the Percentage of Participants Experienced Dose Limiting Toxicities
Időkeret: first treatment cycle, up to 28 days
|
Maximum tolerated dose (MTD) of nintedanib and afatinib based on the Percentage of participants experienced dose limiting toxicities during the dose escalation phase.
|
first treatment cycle, up to 28 days
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Overall Tumour Response Rate Assessed by the Investigator According to the Response Evaluation Criteria In Solid Tumours (RECIST) Version 1.1
Időkeret: 6 weeks
|
The investigator evaluated whether complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD) occurred in a patient. CR for target lesions: Disappearance of all target lesions. CR for non-target lesions: Disappearance of all non-target lesions and normalization of tumour marker level. All lymph nodes must be non-pathological in size (<10mm short axis). PR: At least a 30% decrease in the sum of diameters (SoD) of target lesions taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as references the smallest SoD while on study. PD: At least a 20% increase in the SoD of target lesions, taking as references the smallest sum on study (this includes the baseline sum if that is the smallest on study). Also, the sum must also demonstrate an absolute increase of a least 5mm. Appearance of one or more new lesions |
6 weeks
|
Incidence and Intensity of Adverse Events According to CTCAE (Common Toxicity Criteria Adverse Event) Version 3.0
Időkeret: First treatment administration until cut-off date of 02Oct2014; up to 336 days
|
Incidence and intensity of Adverse Events with grading according to the Common Terminology Criteria for Adverse Events (CTCAE version 3.0).
|
First treatment administration until cut-off date of 02Oct2014; up to 336 days
|
Changes in Safety Laboratory Parameters
Időkeret: First treatment administration until cut-off date of 02 October 2014, up to 336 days
|
Changes in safety laboratory Parameters reported as adverse events
|
First treatment administration until cut-off date of 02 October 2014, up to 336 days
|
Cpre,ss,Norm (Dose Normalized Trough Plasma Concentration of Nintedanib at Steady State)
Időkeret: Day 8, Day 15, Day 22 and Day 28
|
Cpre,ss,norm (Dose normalized trough plasma concentration of nintedanib at steady state) are presented for the 2 MTD treatment groups (continuous administered nintedanib at 150 mg b.i.d. concomitantly with continuously administered afatinib 30 mg q.d. or with intermittently administered afatinib 40 mg q.d.) As nintedanib is given twice daily, samples are taken at Day 8, Day 15, Day 22 and Day 28; the Pharmacokinetic (PK) parameter names will be Cpre,ss,15,norm (Day 8), Cpre,ss,29,norm (Day 15), Cpre,ss,43,norm (Day 22) and Cpre,ss,55,norm (Day 28) |
Day 8, Day 15, Day 22 and Day 28
|
Trough Plasma Concentration of Afatinib at Steady State
Időkeret: Day 7, Day 13, Day 15, Day 22, Day 27 and Day 28
|
C(pre,ss) is defined as pre-dose (trough) concentration of afatinib in plasma at steady state immediately before administration of the next dose. C24,7 corresponds to the plasma concentration at 24 hours on Day 7. C24,13 corresponds to the plasma concentration at 24 hours on Day 13. C24,27 corresponds to the plasma concentration at 24 hours on Day 27. |
Day 7, Day 13, Day 15, Day 22, Day 27 and Day 28
|
Objective Response (OR) During the Expansion Phase
Időkeret: Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)
|
OR is defined as a best overall response of complete response (CR) or partial response (PR) according to RECIST version 1.1, CR for target lesions (TL): Disappearance of all target lesions. CR for non-target lesions (NTL): Disappearance of all non-target lesions. All lymph nodes must be nonpathological in size (<10mm short axis). PR for TL: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. Other factors which add to the overall response of an imaging timepoint as PR are as below: CR in TL, but non-CR/Non-PD in NTL leads to PR CR in TL, but not evaluated NTL leads to PR PR in TL, but non-PD NTL or not all evaluated NTL leads to PR; All the above scenarios should also satisfy 'No occurrence of new lesions'. |
Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)
|
Disease Control (DC) During the Expansion Phase
Időkeret: Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)
|
DC is defined as the best overall response of CR, PR, stable disease (SD) and non-CR/non-PD.
CR for target lesions (TL): Disappearance of all target lesions.
CR for non-target lesions (NTL): Disappearance of all non-target lesions .
All lymph nodes must be non-pathological in size (<10mm short axis).
PR for TL: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.
Other factors which add to the overall response of an imaging timepoint as PR are as below:- CR in TL, but non-CR/Non-PD in NTL leads to PR CR in TL, but not evaluated NTL leads to PR PR in TL, but non-PD NTL or not all evaluated NTL leads to PR; SD for TL: change in the sum of diameters does not satisfy PR or PD.
SD in TL, non-PD in NTL lead to overall response of SD, provided there is no appearance of new lesions.
|
Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)
|
Stable Disease for at Least 12 Weeks During the Expansion Phase
Időkeret: Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)
|
SD: Neither sufficient shrinkage to qualify for PR (Partial response) nor sufficient increase to qualify for PD(Progressive disease), taking as references the smallest sum of diameters SoD while on study. PR: At least a 30% decrease in the sum of diameters (SoD) of target lesions taking as reference the baseline sum diameters. PD: At least a 20% increase in the SoD of target lesions, taking as references the smallest sum on study (this includes the baseline sum if that is the smallest on study). Also, the sum must also demonstrate an absolute increase of a least 5mm. Appearance of one or more new lesions. |
Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)
|
Percentage Change in the Tumour Size From Baseline During the Expansion Phase
Időkeret: Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)
|
Percentage change in the tumour size from baseline is expressed as Number of subjects with maximum decrease from baseline in the sum of longest diameters of target lesions.
|
Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)
|
Együttműködők és nyomozók
Szponzor
Publikációk és hasznos linkek
Hasznos linkek
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Tényleges)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Becslés)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Becslés)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- 1239.14
- 2009-011321-14 (EudraCT szám: EudraCT)
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .
Klinikai vizsgálatok a Neoplazmák
-
European Association for Endoscopic SurgeryVisszavont
-
Fudan UniversityShanghai Zhongshan Hospital; RenJi Hospital; First Hospital of China Medical University és más munkatársakMég nincs toborzás
-
Institut Paoli-CalmettesBefejezveMÉH NYAJNYAKI NEOPLASMAI | ENDOMETRIÁLIS NEOPLASMSFranciaország
Klinikai vizsgálatok a BIBF 1120
-
Boehringer IngelheimMegszűntKarcinóma, nem kissejtes tüdőJapán
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)BefejezveIsmétlődő méh corpus carcinoma | Endometrium tiszta sejtes adenokarcinóma | Endometrium savós adenokarcinóma | Endometrium differenciálatlan karcinóma | Endometrium adenokarcinóma | Endometrium átmeneti sejtes karcinóma | Endometrium mucinous adenocarcinoma | Endometrium laphámsejtes karcinóma | Rosszindulatú...Egyesült Államok
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)BefejezveIsmétlődő pleurális rosszindulatú mesothelioma | IV. szakasz Pleurális MesotheliomaEgyesült Államok
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Boehringer IngelheimBefejezveIsmétlődő nem kissejtes tüdőrák | IV. stádiumú nem kissejtes tüdőrák | Laphámsejtes tüdőrák | III. stádiumú nem kissejtes tüdőrákEgyesült Államok
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Boehringer Ingelheim; National Comprehensive Cancer...BefejezveIsmétlődő vastagbél karcinóma | Ismétlődő végbélrák | Rektális adenokarcinóma | Vastagbél adenokarcinóma | IVA stádiumú vastagbélrák | IVA stádiumú végbélrák | IVB stádiumú vastagbélrák | IVB stádiumú végbélrákEgyesült Államok
-
Boehringer IngelheimBefejezveProsztata neoplazmák
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkBefejezveKarcinoid daganat | Neuroendokrin neoplazma | Áttétes karcinoid tumorEgyesült Államok
-
Boehringer IngelheimBefejezveTüdő-fibrózisArgentína, Ausztrália, Belgium, Brazília, Bulgária, Kanada, Chile, Kína, Cseh Köztársaság, Franciaország, Németország, Görögország, Magyarország, Írország, Olaszország, Koreai Köztársaság, Mexikó, Hollandia, Portugália, Orosz Föderáció és több
-
University College, LondonBoehringer IngelheimBefejezvePetefészekrák | Petevezető rákEgyesült Királyság